HHS to invest in domestic production of essential medical supplies
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Headline
Supplies of Mo-99/Tc-99M, which are medical radioisotopes used in procedures to diagnose and detect diseases including heart disease and cancer, are…
Headline
Baxter announced Oct. 31 that it has restarted its North Cove, N.C. facility's highest-throughput IV solutions manufacturing line, which normally accounts for…
Headline
The AHA Oct. 28 issued a Special Bulletin to members informing them of the Food and Drug Administration's authorization extending the use date for certain…
Headline
In this conversation, Mark Taylor, M.D., surgical director for surgical operations at Cleveland Clinic, discusses the health system's ongoing IV fluid…
Headline
AHA today Oct. 24 a Special Bulletin with updates from Baxter on its efforts to increase access to and supply of IV solutions in response to the effects of…
Headline
The Centers for Disease Control and Prevention has issued a health advisory on the supply disruption of peritoneal dialysis and intravenous solutions due to…